SVASE Main Event: PWC Shaking the MoneyTree September 3, 2009

SVASE Main Event: PWC Shaking the MoneyTree

Start: 09/03/2009 - 6:00pm
End: 09/03/2009 - 8:30pm

Contact Info: Laura Weigant Email: [email protected]

Location: Wilson Sonsini Goodrich & Rosati
950 Page Mill Road, Palo Alto, CA 94304

URL: www.svase.org/?q=node/2026

Shaking the Money Tree

The MoneyTree™ report is the definitive source of information on emerging companies that receive financing and the venture capital firms that provide it. As a collaboration between PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association, it is the only industry-endorsed research of its kind.

Where’s the money going, and who’s putting it?
PricewaterhouseCoopers will unveil the MoneyTree™ report - a quarterly study of global venture capital investment activity - followed by a lively discussion from top venture capitalists who will explore what they perceive as the key current and future trends in venture financing, for Silicon Valley and Globally.
· What are the hot emerging Markets – consumer, business, geographic, social, entertainment?
· What are the hot emerging technologies are being funded – IT, Communications, Mobility, Medical?
· How are these interrelated?
· With the squeeze on the economy, how do you go forward from here?
· Who should you approach to fund YOUR idea?

The Panel:
· Emmett T. Cunningham Jr., MD, Ph.D., MPH, Partner, Clarus Ventures
· Rich Ferrari, Managing Director, De Novo Ventures
· Allan May, Chairman & Founder, Life Science Angels
· Rich Redelfs, General Partner, Foundation Capital
· Pete Scott, , Head of Life Sciences, Silicon Valley Bank
Moderator: Steve Bengston, Managing Director of Emerging Company Services, PricewaterhouseCoopers

WHEN: Thursday, September 36:00 - 7:00 pm: Networking and hors d’oeuvres
7:00 - 8:15 pm: Panel discussion and Q/A
8:15 - 8:30 pm: Additional networking

LOCATION: Wilson Sonsini Goodrich & Rosati (WSGR Campus), 950 Page Mill Road, Palo Alto, CA 94304

PRE-REGISTERED RATES (All Rates Include Hors D’oeuvres):
Members - $20; Affiliates who advertise this event - $29; General Public - $49

Pre-registration closes at 9 PM the night before the event.

WALK-IN RATES: Add $10.00 to the listed price

To reserve an Exhibit Table:
Contact [email protected], $350 Members, $850 Non-members (Includes exhibit table, 2 tickets to the event and 1 year corporate membership).

Seating is limited, so early registration is recommended to avoid disappointment on the day.

This event is co-sponsored by Wilson Sonsini Goodrich & Rosati, www.wsgr.com

If the event is sold out, we apologize that due to fire safety codes we cannot accept any walk-ins.

Speaker Bios

Emmett T. Cunningham Jr., MD, Ph.D., MPH, Partner, Clarus Ventures
Dr. Cunningham joined Clarus Ventures with more than 20 years experience in the biomedical and biopharmaceutical sectors. Prior to Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc, where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology.

Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 200 publications. He is an Adjunct Clinical Professor of Ophthalmology at Stanford University, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University, a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute, and completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF.

Dr. Cunningham is a member of the Board of Directors for SARcode Inc., a member of the Scientific Advisory Boards of ESBAtech AG and Comentis Inc., and a Board observer for Ferrokin Biosciences, Pearl Therapeutics Inc., Taligen Therapeutics Inc., and Zogenix, Inc.

Rich Ferrari, Managing Director, De Novo Ventures
Rich has been a successful CEO of several medical technology companies, both prior to and after co-founding De Novo in 2000. Following De Novo’s investment in CryoVascular Systems, Rich became CEO, growing the initial 5 person start up team to a company of 20 employees. He was instrumental in developing the clinical and product strategies and hiring the executive team. In 2002, Rich led Paracor Medical, another De Novo portfolio company. He grew the company from 4 to 22 employees, refined the product strategy, raised its Series B financing and hired his replacement CEO. Prior to co-founding De Novo Ventures, he was the co-founder and CEO of CardioThoracic Systems (“CTSI”), a company he led to an initial public offering in only 7 months in 1996. CTSI, the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was ultimately acquired by Guidant Corporation in November 1999. Before that, Rich was the CEO of Cardiovascular Imaging Systems (“CVIS”). As CEO, he orchestrated a successful IPO and ultimately sold the company to Boston Scientific Corporation in 1995.

In addition, Rich founded Saratoga Ventures in 1996, a venture capital partnership that has provided seed financing to startup medical technology companies, including Atrionix, Oratec, Enteric Medical, Trivascular, and Endotex. At Saratoga, Rich was Chairman of Oratec, which was sold in 2001 to Smith & Nephew PLC. Mr. Ferrari also co-founded The Medical Technology Group, which spun out Integrated Vascular Systems, an early stage femoral artery closure company which was sold to Abbott and Angiosense, a needle-free, jet injection, local drug delivery company. Early in his career, Rich held the position of Executive Vice President and General Manager of ADAC Laboratories. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.

Rich sits on the boards of BenVenue, CardioMind, MyoScience, Ovalis, Paracor Medical, Pulmonx, Simpirica, Spinal Kinetics and Spinal Modulation. His prior board involvement includes TriVascular.

Rich Redelfs, General Partner, Foundation Capital
Rich joined Foundation Capital in 2004 after more than 20 years in networking and communications, amassing a combination of start-up entrepreneurial as well as large company intrapreneurial experience. Most recently, he was president and CEO of Atheros Communications, which he helped build into the leading provider of Wi-Fi wireless semiconductors; it was subsequently named "Silicon Valley's Fastest Growing Private Company" by the Silicon Valley/San Jose Business Journal and PricewaterhouseCoopers for the 2001—2003 period. In 2003 Rich received Frost & Sullivan's prestigious "Wireless LAN CEO of the Year" award.

Rich currently serves on the boards of Dust Networks, Mobius Microsystems, Prematics, ACCO Semiconductor and Ventiva, and was previously on the boards of Azimuth Systems and Atheros Communications. He has an MBA from Harvard Business School and a BSIE from Purdue.

Peter R. Scott, Head of Life Sciences, Silicon Valley Bank
Pete Scott is currently the Head of Life Sciences for the Bank’s Life Science Practice on the West Coast. In addition, Mr. Scott leads the Southern California technology practice for SVB’s commercial bank. Responsibilities include management and leadership of the Bank’s Life Science effort including the development of new relationships with life science companies headquartered on the West Coast, developing and expanding relationships with the life science venture capital community on the West Coast, and contributing to SVB’s status as a thought leader within the Life Science community. Mr. Scott has historically held various senior positions at Silicon Valley Bank including Senior Vice President and Manager of the Life Sciences Team, Communications & Electronics Team, and Semiconductor Team. Over Mr. Scott’s twelve-year tenure with Silicon Valley Bank, he has worked with a wide range of high tech and life science companies including those in the biotechnology, medical devices, semiconductor, and telecommunications industries. Prior to joining Silicon Valley Bank, Mr. Scott spent six years as a senior lender in the Commercial Lending Division of Wells Fargo Bank.

Mr. Scott received his B.S in Business Administration from Northern Illinois University in 1989.

Steve Bengston, Managing Director of Emerging Company Services, PricewaterhouseCoopers
Steve is Managing Director of Emerging Company Services (ECS) at PricewaterhouseCoopers. ECS acts as “mentor capitalists” for young, high potential companies and assists them with a variety of services, including, Reviewing Executive Summaries/Investor Presentations, Referrals, Raising Money, Partnerships and Finding People. ECS works closely with the leading opinion leaders/influencers in the Bay Area, including venture capitalists, attorneys, bankers and other service providers that have made Silicon Valley the leading high tech center in the world.

Before joining PwC, Steve had 20 years of experience in a variety of marketing, business development and general management roles at several high tech companies in the Bay Area. Most recently, he was Pres/CEO of ynot.com, a leading international emarketing and greeting card company. Previously, he was VP Marketing & Business Development at Worldview Systems, an Internet travel pioneer. At Worldview, Steve helped launch and market Travelocity with Sabre Interactive.

Steve has a BA in Economics and MBA from Stanford University. He works closely or sits on the Advisory Board at Churchill Club, SVASE, SDForum, Financing Partners, Life Science Angels, and the Stanford/MIT Venture Lab, has taught classes on funding/running start ups at UC Berkeley, Santa Clara Law School, Hastings Law School, and Stanford, and is active in a variety of other organizations in the Bay Area targeting entrepreneurs and investors. He is a frequent moderator/panelist at both university and industry sponsored events.

Official Website: http://www.svase.org/?q=node/2026